NETRI Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
47
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
10
NETRI General Information
Description
Developer of biological research tools designed to simulate human biology for drug testing. The company's tools combine human neural stem cells, organs-on-chip technology, and AI-driven algorithms to reproduce neural data, enabling researchers to assess drug efficacy and toxicity, and diagnose diseases by analyzing digital signatures, offering customizable models for food safety, pain management, dermatology, and neurodegenerative disorders.
Contact Information
Website
www.netri.comCorporate Office
- 76 Rue Georges Gouy
- 69007 Lyon
- France
Corporate Office
- 76 Rue Georges Gouy
- 69007 Lyon
- France
NETRI Timeline
NETRI Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Accelerator/Incubator | 16-Oct-2026 | Completed | Generating Revenue | |||
| 6. Accelerator/Incubator | 24-Jun-2026 | Completed | Generating Revenue | |||
| 5. Accelerator/Incubator | 01-Jan-2026 | Completed | Generating Revenue | |||
| 4. Later Stage VC | 04-Feb-2025 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series B) | Completed | Generating Revenue | ||||
| 2. Early Stage VC (Series A) | 26-Apr-2022 | $8.72M | $9.3M | Completed | Generating Revenue | |
| 1. Early Stage VC | 01-Apr-2020 | $586K | $586K | Completed | Generating Revenue |
NETRI Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
NETRI Comparisons
Industry
Financing
Details
NETRI Competitors (13)
One of NETRI’s 13 competitors is TissUse, a Accelerator/Incubator Backed company based in Berlin, Germany.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| TissUse | Accelerator/Incubator Backed | Berlin, Germany | ||||
| React4life | Accelerator/Incubator Backed | Genova, Italy | ||||
| Curi Bio | Venture Capital-Backed | Seattle, WA | ||||
| Aracari Biosciences | Accelerator/Incubator Backed | San Diego, CA | ||||
| SynVivo | Corporation | Huntsville, AL |
NETRI Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
NETRI Patents
NETRI Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026176125-A1 | Method for evaluating the effects of a stimulus on a reproduction of a target organ and multi-compartment organ-on-chip enabling the implementation thereof | Pending | 24-Feb-2025 | ||
| FR-3172510-A1 | Method for evaluating the effects of a stimulus on the reproduction of a target organ and multicompartmental organ-on-chip enabling its implementation | Pending | 24-Feb-2025 | ||
| WO-2026099439-A1 | Multi-compartment organ-on-a-chip for reproducing and functionalizing a mucosa | Pending | 08-Nov-2024 | ||
| WO-2026099440-A1 | Multi-compartment organ-on-a-chip for reproducing and functionalizing a skin model | Pending | 08-Nov-2024 | ||
| WO-2026099438-A1 | Multi-compartment organ-on-a-chip for reproducing and functionalizing a target organ | Pending | 08-Nov-2024 | C12M23/16 |
NETRI Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
NETRI Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| La French Tech | Accelerator/Incubator | |||
| 3DEXPERIENCE Lab | Accelerator/Incubator | |||
| Merck Digital Sciences Studio | Accelerator/Incubator | Minority | ||
| Clery | Impact Investing | Minority | ||
| Treviso Capital | Special Purpose Acquisition Company (SPAC) | Minority |
NETRI Acquisitions (1)
NETRI’s most recent deal was a Merger/Acquisition with HCS Pharma. The deal was made on 25-Mar-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| HCS Pharma | 25-Mar-2025 | Merger/Acquisition | Biotechnology |
NETRI FAQs
-
When was NETRI founded?
NETRI was founded in 2018.
-
Where is NETRI headquartered?
NETRI is headquartered in Lyon, France.
-
What is the size of NETRI?
NETRI has 47 total employees.
-
What industry is NETRI in?
NETRI’s primary industry is Medical Supplies.
-
Is NETRI a private or public company?
NETRI is a Private company.
-
What is NETRI’s current revenue?
The current revenue for NETRI is .
-
How much funding has NETRI raised over time?
NETRI has raised $14.5M.
-
Who are NETRI’s investors?
La French Tech, 3DEXPERIENCE Lab, Merck Digital Sciences Studio, Clery, and Treviso Capital are 5 of 10 investors who have invested in NETRI.
-
Who are NETRI’s competitors?
TissUse, React4life, Curi Bio, Aracari Biosciences, and SynVivo are some of the 13 competitors of NETRI.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
